CRL · Charles River Laboratories International

The thesis

Charles River Laboratories' preclinical recovery passed its 4 November 2026 test. Organic growth beat guidance, orders still ran ahead of revenue and the 2026 earnings range went up. The view is a modestly better than even chance that the shares lead the S&P 500 over three months. The fourth-quarter report, estimated for 17 February 2027, settles whether bookings at the drug-testing business keep running ahead of revenue and turn into 2027 growth.

Organic revenue, which excludes acquisitions, divestitures and currency, grew 4.7% in the third quarter, per the company's 4 November 2026 release. Net book-to-bill (new orders divided by revenue) at Discovery and Safety Assessment (DSA), the preclinical testing segment, was 1.09 times. The 2026 non-GAAP earnings per share (EPS) range rose to $11.35–$11.55 from $11.15–$11.45.

On 9 November 2026 Charles River agreed to buy the bioanalysis and drug metabolism and pharmacokinetics (DMPK) businesses of Frontage Laboratories. It will pay about $470 million in cash, plus up to $75 million tied to performance. The company expects the deal to be neutral to non-GAAP EPS in 2027 and accretive after that, so it adds clinical testing scale without changing the near-term earnings test.

The price already reflects the raised guide. The 11 November 2026 close of $342.69 sits above the $333.43 average analyst target that fiscal.ai reported on 5 November 2026.

Bullish and bearish views on Charles River Laboratories International, Inc.

The bull case on Charles River Laboratories International, Inc. (CRL), in brief: organic growth beat the guided range. The bear case: order momentum slowed from the second quarter.

Bull case

• Organic growth beat the guided range. Third-quarter organic revenue grew 4.7%, per the 4 November 2026 release, and the 2026 organic guide moved to at least 1.5% from 0%–1%. DSA organic revenue rose 5.9% and Manufacturing rose 7.4%.
• Earnings and margin both moved up. Third-quarter non-GAAP EPS was $3.09 against $2.43 a year earlier, per the release. Non-GAAP operating margin reached 23.0% from 19.7%, close to the roughly 24% target for 2030 set at the 24 September 2026 Investor Day.
• Orders still run ahead of revenue. On the 4 November 2026 call, management reported DSA net bookings of $652 million, up 32% from a year earlier. Book-to-bill has stayed above one for four straight quarters, and backlog stood at $2.03 billion.
• Frontage deal widens clinical bioanalysis. The 9 November 2026 release says the Exton, Pennsylvania businesses employ about 340 people across two sites, including a CLIA-certified central laboratory. Charles River said the units made up about 40% of Frontage's 2025 revenue of $256.7 million and will report inside DSA.
• Analysts raised targets above the share price. After the report, Evercore ISI moved to $400 from $330, UBS to $387 from $357, Jefferies to $385 from $340, Barclays to $375 from $330, Baird to $364 from $334 and RBC to $352 from $322, per Benzinga, MarketBeat and StockAnalysis on 5 November 2026 and 6 November 2026. TD Cowen raised its target to $388 from $325 on 11 November 2026, per fiscal.ai.

Bear case

• Order momentum slowed from the second quarter. DSA net book-to-bill fell to 1.09 times in the third quarter from 1.19 times in the second, per the 4 November 2026 and 5 August 2026 calls. Net bookings were $652 million against $701 million.
• Pricing gives no help until late 2027. Benzinga reported from the 4 November 2026 call that the company expects no pricing benefit until at least the second half of 2027. Until then, margin gains depend on volume and cost savings.
• Part of the earnings raise came from tax. The 4 November 2026 release names stronger DSA performance and a lower tax rate as the drivers of the higher non-GAAP range. The GAAP range of $8.15–$8.35 also includes a one-time reversal of acquired tax reserves.
• The price sits above the average target. The $342.69 close on 11 November 2026 is above the $333.43 average target fiscal.ai reported on 5 November 2026. Mizuho lifted its target only to $315 from $295, per StockAnalysis on 6 November 2026.
• The acquisition adds debt and closing risk. The 9 November 2026 release says the deal is funded from the credit facility and cash, and needs Frontage shareholder and regulatory approvals before an expected first-half 2027 close.
• Insiders sold into the rally. SEC Form 4 filings show director James C. Foster sold 24,042 shares at $350.00 on 22 October 2026 and 33,561 shares at $300.00 on 25 August 2026, both under Rule 10b5-1 plans. DSA head Shannon Parisotto sold 2,156 shares at $344.41 on 21 October 2026 under a plan.
• Research models are still shrinking. Research Models and Services organic revenue fell 0.6% in the third quarter of 2026 and 1.4% in the second, per the company's releases. The segment carries NIH and academic-funding exposure.

Price setup

The shares closed at $342.69 on 11 November 2026, 9.7% below the 52-week intraday high of $379.63 set on 29 October 2026. The 3-month change is 21.8%, measured from a close of $281.27 on 13 August 2026. The 52-week closing low was $149.93 on 18 May 2026.

As of 11 November 2026, the 50-day moving average was $309.19 and the 200-day was $226.46, both well under the last close. The report itself moved the shares down: they closed at $326.29 on 4 November 2026 and $313.02 on 5 November 2026. They then recovered to $337.52 on 6 November 2026 and $353.34 on 9 November 2026, the day of the Frontage announcement, before easing to $345.80 and $342.69.

The case turns on two levels. The 50-day average near $309 marks where the post-report dip found buyers. The 13 August 2026 close of $281.27 marks the start of the Investor Day and third-quarter advance. A close under the 50-day average would put the post-report recovery in question. The kill line sits below the 13 August 2026 close.

Catalysts ahead

• ~2 December 2026 (est.): Possible December investor conference appearance; Charles River presented at Evercore's healthcare conference on 3 December 2025, and no 2026 date is announced. Any management comment on fourth-quarter DSA bookings or the Frontage deal would be the only company read on orders before the year-end report.
• ~17 February 2027 (est.): Fourth-quarter 2026 earnings report and full-year 2027 outlook. Shows whether DSA book-to-bill stays above one after 1.09x, whether 2026 organic growth meets the at-least-1.5% guide, and whether the 2027 guide fits the 5%–7% Investor Day target with Frontage included.
• ~30 June 2027 (est.): Expected closing of the Frontage bioanalysis and DMPK acquisition, guided for the first half of 2027. Closing on time, after Frontage shareholder and regulatory approvals, starts the clinical bioanalysis contribution the company says is EPS-neutral in 2027 and accretive after.

What would change the view

A daily close below $270, under the 13 August 2026 close of $281.27, which would erase the whole Investor Day and third-quarter advance. A DSA net book-to-bill below one or a cut to the 2026 non-GAAP EPS range of $11.35–$11.55 would also break the case.

The risks this note tracks, each with what would confirm it:

• Preclinical orders slow enough that bookings no longer run ahead of revenue, undermining the 5%–7% organic growth target for 2027–2030. Confirmed by: DSA net book-to-bill below one at the fourth-quarter report, after 1.19x in the second quarter and 1.09x in the third.
• Pricing stays flat for longer than management expects, capping DSA margin recovery. Confirmed by: management pushing the expected pricing benefit beyond the second half of 2027, or DSA non-GAAP operating margin falling below the 26.8% reported for the third quarter of 2026.
• The Frontage acquisition dilutes earnings or slips, adding debt without the promised clinical growth. Confirmed by: a 2027 non-GAAP EPS guide that shows the deal as dilutive, or a closing pushed beyond the first half of 2027.
• Academic and government funding keeps research-model volumes weak. Confirmed by: a further quarter of negative Research Models and Services organic growth, after declines of 1.4% and 0.6% in the second and third quarters of 2026.
• FDA moves away from animal testing, and tools such as virtual control groups, shrink animal demand per preclinical study over time. Confirmed by: management citing regulatory changes or lower animal use for weaker safety-assessment or research-model demand.

What it trades with

DSA demand follows biotech and pharmaceutical research budgets, so the shares tend to move with biotech funding conditions and preclinical outsourcing peers. The Frontage businesses, once closed, add exposure to clinical-stage drug testing, where most of Frontage's 2025 bioanalysis revenue came from, per the 9 November 2026 release. Research Models and Services adds exposure to NIH and academic budgets. Since May 2026, divestitures have shrunk reported revenue, so organic growth is the only like-for-like measure against peers. The three-month gain to 11 November 2026 came mostly from company events: the 24 September 2026 Investor Day, the 4 November 2026 report and the 9 November 2026 deal.